{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:19:13Z","timestamp":1793697553947,"version":"4.5.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11255-019-02290-3","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T02:04:17Z","timestamp":1571018657000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Sclerostin: a new biomarker of CKD\u2013MBD"],"prefix":"10.1007","volume":"52","author":[{"given":"Andreja","family":"Figurek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1048-2579","authenticated-orcid":false,"given":"Merita","family":"Rroji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goce","family":"Spasovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"2290_CR1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW (2013) Chronic kidney disease: global dimension and perspectives. The Lancet 382:260\u2013272","journal-title":"The Lancet"},{"key":"2290_CR2","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2005101085","volume":"17","author":"M Tonelli","year":"2006","unstructured":"Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX (2006) Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17:2034\u20132047","journal-title":"J Am Soc Nephrol"},{"key":"2290_CR3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"2290_CR4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bone.2017.01.023","volume":"100","author":"KA Hruska","year":"2017","unstructured":"Hruska KA, Sugatani T, Agapova O, Fang Y (2017) The chronic kidney disease-mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone 100:80\u201386","journal-title":"Bone"},{"key":"2290_CR5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D\u2019Agostin D, Kurahara C, Gao Y, Cao J, Gong J et al (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860\u2013869","journal-title":"J Bone Miner Res"},{"key":"2290_CR6","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","volume":"22","author":"DG Winkler","year":"2003","unstructured":"Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K et al (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267\u20136276","journal-title":"EMBO J"},{"key":"2290_CR7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2015.156","volume":"88","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel P, D\u2019Haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88:235\u2013240","journal-title":"Kidney Int"},{"key":"2290_CR8","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1093\/ndt\/gft039","volume":"28","author":"L Viaene","year":"2013","unstructured":"Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D\u2019Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28:3024\u20133030","journal-title":"Nephrol Dial Transplant"},{"key":"2290_CR9","doi-asserted-by":"crossref","first-page":"25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ (2011) Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependently pathway. PLoS ONE 6:25900","journal-title":"PLoS ONE"},{"key":"2290_CR10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33:747\u2013783","journal-title":"Endocr Rev"},{"key":"2290_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/bonekey.2013.95","volume":"2","author":"BL Clarke","year":"2013","unstructured":"Clarke BL, Drake MT (2013) Clinical utility of serum sclerostin measurements. Bonekey Rep. 2:361. \nhttps:\/\/doi.org\/10.1038\/bonekey.2013.95","journal-title":"Bonekey Rep."},{"key":"2290_CR12","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.17219\/acem\/68739","volume":"26","author":"B Pietrzyk","year":"2017","unstructured":"Pietrzyk B, Smertka M, Chudek J (2017) Sclerostin: intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders. Adv. Clin. Exp. Med 26:1283\u20131291","journal-title":"Adv. Clin. Exp. Med"},{"key":"2290_CR13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/BF03401318","volume":"13","author":"MP Yavropoulou","year":"2014","unstructured":"Yavropoulou MP, Xygonakis C, Lolou M, Karaimou F, Yovos JG (2014) The sclerostin story: from human genetics to the development of novel anabolic treatment or osteoporosis. Hormones 13:476\u2013487","journal-title":"Hormones"},{"key":"2290_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41100-016-0024-4","volume":"2","author":"Y Asamiya","year":"2016","unstructured":"Asamiya Y, Tsuchiya K, Nitta K (2016) Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder. Renal Replace Ther 2:8. \nhttps:\/\/doi.org\/10.1186\/s41100-016-0024-4","journal-title":"Renal Replace Ther"},{"key":"2290_CR15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2215\/CJN.07670712","volume":"8","author":"S Pelletier","year":"2013","unstructured":"Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD0. Clin J Am Soc Nephrol 8:819\u2013823","journal-title":"Clin J Am Soc Nephrol"},{"key":"2290_CR16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ndt\/gfr270","volume":"27","author":"D Cejka","year":"2011","unstructured":"Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmaye C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B et al (2011) Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 27:226\u2013230","journal-title":"Nephrol Dial Transplant"},{"key":"2290_CR17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D, Marculescu R, Kozakowski N et al (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99:248\u2013255","journal-title":"J Clin Endocrinol Metab"},{"key":"2290_CR18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000364992","volume":"38","author":"BO Bielesz","year":"2014","unstructured":"Bielesz BO, Hempfing T, Kieweg H, Marculescu R, Haas M, Cejka D (2014) Sclerostin declines during hemodialysis and appears in dialysate. Blood Purif 38:30\u201336","journal-title":"Blood Purif"},{"key":"2290_CR19","first-page":"1217","volume":"32","author":"L Lips","year":"2017","unstructured":"Lips L, de Roij van Zuijdewijn CLM, Ter Wee PM, Bots ML, Blankestijn PJ, van den Dorpel MA, Fouque D, de Jongh R, Pelletier S, Vervloet MG et al (2017) Serum sclerostin: relation with mortality and impact of hemodiafiltration. Nephrol Dial Transplant 32:1217\u20131223","journal-title":"Nephrol Dial Transplant"},{"key":"2290_CR20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/nep.12509","volume":"20","author":"S Yamada","year":"2015","unstructured":"Yamada S, Tsuruya K, Tokumoto M, Yoshida H, Ooboshi H, Kitazono T (2015) Factors associated with serum soluble inhibitors of Wnt-\u03b2-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis. Nephrology (Carlton) 20:639\u2013645","journal-title":"Nephrology (Carlton)"},{"key":"2290_CR21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000355781","volume":"39","author":"M Bonani","year":"2014","unstructured":"Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Graf N, Frey D, W\u00fcthrich RP (2014) Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res 39:230\u2013239","journal-title":"Kidney Blood Press Res"},{"key":"2290_CR22","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1097\/TP.0000000000001311","volume":"100","author":"P Evenepoel","year":"2016","unstructured":"Evenepoel P, Claes K, Viaene L, Bammens B, Meijers B, Naesens M, Sprangers B, Kuypers D (2016) Decreased circulating sclerostin levels in renal transplant recipients with persistent hyperparathyroidism. Transplantation 100:2188\u20132193","journal-title":"Transplantation"},{"key":"2290_CR23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jbmr.1630","volume":"27","author":"Y Sabbagh","year":"2012","unstructured":"Sabbagh Y, Graciolli FG, O\u2019Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C et al (2012) Repression of osteocyte Wnt\/-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27:1757\u20131772","journal-title":"J Bone Miner Res"},{"key":"2290_CR24","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1210\/jc.2014-2372","volume":"99","author":"E Ishimura","year":"2014","unstructured":"Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M (2014) Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 99:4315\u20134320","journal-title":"J Clin Endocrinol Metab"},{"key":"2290_CR25","doi-asserted-by":"crossref","first-page":"E1854","DOI":"10.1210\/jc.2014-2042","volume":"99","author":"M Kanbay","year":"2014","unstructured":"Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S et al (2014) Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients. J Clin Endocrinol Metab 99:E1854\u2013E1861","journal-title":"J Clin Endocrinol Metab"},{"key":"2290_CR26","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/ndt\/gfu301","volume":"30","author":"C Drechsler","year":"2015","unstructured":"Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker F, Brandenburg VM (2015) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30:288\u2013293","journal-title":"Nephrol Dial Transplant"},{"key":"2290_CR27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1359\/jbmr.090730","volume":"25","author":"I Kramer","year":"2010","unstructured":"Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178\u2013189","journal-title":"J Bone Miner Res"},{"key":"2290_CR28","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1210\/jc.2009-1909","volume":"95","author":"K Wesseling-Perry","year":"2010","unstructured":"Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, J\u00fcppner H, Salusky IB (2010) The calcemic response to continuous parathyroid hormone (PTH) (1\u201334) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH (7\u201384). J Clin Endocrinol Metab 95:2772\u20132780","journal-title":"J Clin Endocrinol Metab"},{"key":"2290_CR29","doi-asserted-by":"crossref","first-page":"e0176411","DOI":"10.1371\/journal.pone.0176411","volume":"12","author":"GJ Behets","year":"2017","unstructured":"Behets GJ, Viaene L, Meijers B, Blocki F, Brandenburg VM, Verhulst A, D\u2019Haese PC, Evenepoel P (2017) Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLoS One 12:e0176411","journal-title":"PLoS One"},{"key":"2290_CR30","doi-asserted-by":"crossref","first-page":"E1854","DOI":"10.1210\/jc.2014-2042","volume":"99","author":"L Desjardins","year":"2014","unstructured":"Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA (2014) Uremic toxicity and sclerostin in chronic kidney disease patients. J Clin Endocrinol Metab 99:E1854\u2013E1861","journal-title":"J Clin Endocrinol Metab"},{"key":"2290_CR31","doi-asserted-by":"crossref","first-page":"e0178637","DOI":"10.1371\/journal.pone.0178637","volume":"12","author":"L Tartaglione","year":"2017","unstructured":"Tartaglione L, Pasquali M, Rotondi S, Muci ML, Leonangeli C, Farcomeni A, Fassino V, Mazzaferro S (2017) Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS One 12:e0178637","journal-title":"PLoS One"},{"key":"2290_CR32","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/ndt\/gft234","volume":"28","author":"RB de Oliveira","year":"2013","unstructured":"de Oliveira RB, Graciolli FG, dos Reis LM, Cancela ALE, Cuppari L, Canziani ME, Carvalho AB, Jorgetti V, Moyses RMA (2013) Disturbances of Wnt\/\u03b2-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant 28:2510\u20132517","journal-title":"Nephrol Dial Transplant"},{"key":"2290_CR33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1681\/ASN.2006050490","volume":"18","author":"S Mathew","year":"2007","unstructured":"Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA (2007) Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 18:122\u2013130","journal-title":"J Am Soc Nephrol"},{"key":"2290_CR34","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1073\/pnas.1221255110","volume":"110","author":"ZC Ryan","year":"2013","unstructured":"Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, Westendorf JJ, Singh RJ, Kumar R (2013) Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc. Natl Acad Sci U S A 110:6199\u20136204","journal-title":"Proc. Natl Acad Sci U S A"},{"key":"2290_CR35","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1681\/ASN.2014020166","volume":"25","author":"R Kumar","year":"2014","unstructured":"Kumar R, Vallon V (2014) Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis. J Am Soc Nephrol 25:2159\u20132168","journal-title":"J Am Soc Nephrol"},{"key":"2290_CR36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1479164117742316","volume":"15","author":"C Zeng","year":"2018","unstructured":"Zeng C, Guo C, Cai J, Tang C, Dong Z (2018) Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diabetes Vasc Dis Res 15:99\u2013105","journal-title":"Diabetes Vasc Dis Res"},{"key":"2290_CR37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2016.08.003","volume":"253","author":"XW He","year":"2016","unstructured":"He XW, Wang E, Bao YY, Wang F, Zhu M, Hu XF, Jin XP (2016) High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke. Atherosclerosis 253:22\u201328","journal-title":"Atherosclerosis"},{"key":"2290_CR38","first-page":"2816","volume":"11","author":"IC Teng","year":"2018","unstructured":"Teng IC, Wang JH, Lee CJ, Hou JS, Hsu BG (2018) Serum sclerostin as an independent marker of peripheral artery disease in elderly persons. Int. J. Clin. Exp. Pathol 11:2816\u20132821","journal-title":"Int. J. Clin. Exp. Pathol"},{"key":"2290_CR39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1479164113510923","volume":"11","author":"A Gaudio","year":"2014","unstructured":"Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisar R, Fiore CE (2014) The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Diabetes Vasc Dis Res 11:48\u201352","journal-title":"Diabetes Vasc Dis Res"},{"key":"2290_CR40","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s11255-018-1935-5","volume":"50","author":"A Figurek","year":"2018","unstructured":"Figurek A, Spasovski G (2018) Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder? Int Urol Nephrol 50:1863\u20131870","journal-title":"Int Urol Nephrol"},{"key":"2290_CR41","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2337\/dc12-1691","volume":"36","author":"S Morales-Santana","year":"2013","unstructured":"Morales-Santana S, Garcia-Fontana B, Garcia-Martin A, Rozas-Moreno R, Garcia-Solcedo JA, Reyes-Garcia R, Munoz-Torres M (2013) Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 36:1667\u20131674","journal-title":"Diabetes Care"},{"key":"2290_CR42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2013.05.010","volume":"56","author":"G Hampson","year":"2013","unstructured":"Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML (2013) The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone 56:42\u201347","journal-title":"Bone"},{"key":"2290_CR43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/rheumatology\/kev410","volume":"55","author":"RD Chapurlat","year":"2016","unstructured":"Chapurlat RD, Confavreux CB (2016) Novel biological markers of bone: from bone metabolism to bone physiology. Rheumatology 55:1714\u20131725","journal-title":"Rheumatology"},{"key":"2290_CR44","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11255-016-1379-8","volume":"48","author":"W Lv","year":"2016","unstructured":"Lv W, Guan L, Zhang Y, Yu S, Cao B, Ji Y (2016) Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int Urol Nephrol 48:2043\u20132050","journal-title":"Int Urol Nephrol"},{"key":"2290_CR45","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","volume":"37","author":"SM Krischna","year":"2017","unstructured":"Krischna SM, Seto SW, Jose RJ, Li J, Morton SK, Biros E, Wang Y, Nsengiyumva V, Lindeman JHN, Loots GG et al (2017) Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II\u2013induced aortic aneurysm and atherosclerosis. Arterioscler Thromb Vasc Biol 37:553\u2013566","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2290_CR46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/nep.12813","volume":"22","author":"XR Wang","year":"2017","unstructured":"Wang XR, Yuan L, Zhang JJ, Hao L, Wang DG (2017) Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3\u20135D. Nephrology 22:286\u2013292","journal-title":"Nephrology"},{"key":"2290_CR47","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s11255-017-1604-0","volume":"49","author":"H Zhou","year":"2017","unstructured":"Zhou H, Yang M, Li M, Cui L (2017) Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study. Int Urol Nephrol 49:1433\u20131437","journal-title":"Int Urol Nephrol"},{"key":"2290_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-018-2033-4","volume-title":"Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study","author":"M Li","year":"2018","unstructured":"Li M, Zhou H, Yang M, Xing C (2018) Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Urol. Nephrol, Int. \nhttps:\/\/doi.org\/10.1007\/s11255-018-2033-4"},{"key":"2290_CR49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5414\/CN109333","volume":"90","author":"HS J\u00f8rgensen","year":"2018","unstructured":"J\u00f8rgensen HS, Winther S, Dupont L, B\u00f8ttcher M, Rejnmark L, Hauge EM, Svensson M, Ivarsen P (2018) Sclerostin is not associated with cardiovascular event or fracture in\u00a0kidney\u00a0transplantation candidates. Clin Nephrol 90:18\u201326","journal-title":"Clin Nephrol"},{"key":"2290_CR50","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ndt\/gfv043","volume":"30","author":"CY Yang","year":"2015","unstructured":"Yang CY, Chang ZF, Chau YP, Chen A, Yang WC, Yang AH, Lee OKS (2015) Circulating Wnt\/\u03b2-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant 30:1356\u20131363","journal-title":"Nephrol Dial Transplant"},{"key":"2290_CR51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000443845","volume":"132","author":"G Jean","year":"2016","unstructured":"Jean G, Chazot C, Bresson E, Zaoui E, Cavalier E (2016) High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 132:181\u2013190","journal-title":"Nephron"},{"key":"2290_CR52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nefro.2015.07.006","volume":"36","author":"A Kirkpantur","year":"2016","unstructured":"Kirkpantur A, Balci M, Turkvatan A, Afsar B (2016) Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia 36:24\u201332","journal-title":"Nefrologia"},{"key":"2290_CR53","first-page":"8822","volume":"22","author":"YQ Ji","year":"2018","unstructured":"Ji YQ, Guan LN, Yu SX, Yin PY, Shen XQ, Sun ZW, Liu J, Lv W, Yu GP, Ren C (2018) Serum sclerostin as a potential novel biomarker for heart valve calcification in patients with chronic kidney disease. Eur. Rev. Med. Pharmacol. Sci 22:8822\u20138829","journal-title":"Eur. Rev. Med. Pharmacol. Sci"},{"key":"2290_CR54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12882-018-1046-7","volume":"19","author":"A Chen","year":"2018","unstructured":"Chen A, Sun Y, Cui J, Zhao B, Wang H, Chen X, Mao Y (2018) Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis. BMC Nephrol 19:264","journal-title":"BMC Nephrol"},{"key":"2290_CR55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000368502","volume":"40","author":"A Nowak","year":"2015","unstructured":"Nowak A, Artunc F, Serra AL, Pollock E, Krayenb\u00fchl PA, M\u00fcller C, Friedrich B (2015) Sclerostin quo vadis?\u2014Is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press Res 40:266\u2013276","journal-title":"Kidney Blood Press Res"},{"key":"2290_CR56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00059-013-3992-y","volume":"40","author":"M Balci","year":"2015","unstructured":"Balci M, Kirkpantur A, Turkvatan A, Mandiroglu S, Ozturk E, Afsar B (2015) Sclerostin as a new key player in arteriovenous fistula calcification. Herz 40:289\u2013297","journal-title":"Herz"},{"key":"2290_CR57","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11255-018-1795-z","volume":"50","author":"L Gong","year":"2018","unstructured":"Gong L, Zheng D, Yuan J, Cao L, Ni Z, Fang W (2018) Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients. Int Urol Nephrol 50:955\u2013961","journal-title":"Int Urol Nephrol"},{"key":"2290_CR58","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1210\/jc.2015-3056","volume":"100","author":"P Evenepoel","year":"2015","unstructured":"Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M (2015) Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab 100:4669\u20134676","journal-title":"J Clin Endocrinol Metab"},{"key":"2290_CR59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000366449","volume":"128","author":"P Delanaye","year":"2014","unstructured":"Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L, Bruyere O, Reginster JY, Pottel H, Cavalier E (2014) E Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 128:127\u2013134","journal-title":"Nephron Clin Pract"},{"key":"2290_CR60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.kint.2016.03.028","volume":"90","author":"SC Schiavi","year":"2016","unstructured":"Schiavi SC, Moyses RM (2016) Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast beta-catenin pathway. Kidney Int 90:17\u201320","journal-title":"Kidney Int"},{"key":"2290_CR61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/EJE-14-0106","volume":"171","author":"A Catalano","year":"2014","unstructured":"Catalano A, Pintaudi B, Morabito N, Di Vieste G, Giunta L, Bruno ML, Cucinotta D, Lasco A, Di Benedetto A (2014) Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus. Eur J Endocrinol 171:293\u2013300","journal-title":"Eur J Endocrinol"},{"key":"2290_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-018-2050-3","volume-title":"Relationship between plasma levels of sclerostin, calcium\u2013phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients","author":"B Pietrzyk","year":"2018","unstructured":"Pietrzyk B, Wyskida K, Ficek J, Kolonko A, Ficek R, Wiecek A, Olszanecka-Glinianowicz M, Chudek J (2018) Relationship between plasma levels of sclerostin, calcium\u2013phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients. Urol. Nephrol, Int. \nhttps:\/\/doi.org\/10.1007\/s11255-018-2050-3"},{"key":"2290_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-018-0491-4","author":"H Boltenst\u00e5l","year":"2018","unstructured":"Boltenst\u00e5l H, Qureshi AR, Behets GJ, Lindholm B, Stenvinkel P, D\u2019Haese PC, Haarhaus M (2018) Association of serum sclerostin with bone sclerostin in chronic kidney disease is lost in glucocorticoid treated patients. Calcif Tissue Int. \nhttps:\/\/doi.org\/10.1007\/s00223-018-0491-4","journal-title":"Calcif Tissue Int"},{"key":"2290_CR64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2369-14-219","volume":"14","author":"VM Brandenburg","year":"2013","unstructured":"Brandenburg VM, Kramann R, Koos R, Kr\u00fcger T, Schurgers L, M\u00fchlenbruch G, H\u00fcber S, Gladziwa U, Drechsler C, Ketteler M (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219","journal-title":"BMC Nephrol"},{"key":"2290_CR65","doi-asserted-by":"crossref","first-page":"e19595","DOI":"10.1371\/journal.pone.0019595","volume":"6","author":"D Zhu","year":"2011","unstructured":"Zhu D, Mackenzie NC, Mill\u00e1n JL, Farquharson C, Mac Rae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 6:e19595","journal-title":"PLoS One"},{"key":"2290_CR66","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2369-15-190","volume":"15","author":"FL Carvalho Goncalves","year":"2014","unstructured":"Carvalho Goncalves FL, Elias RM, dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, Jorgetti V, Moyses RMA (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15:190","journal-title":"BMC Nephrol"},{"key":"2290_CR67","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11255-016-1387-8","volume":"48","author":"M Kanbay","year":"2016","unstructured":"Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, Covic A (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48:2029\u20132042","journal-title":"Int Urol Nephrol"},{"key":"2290_CR68","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00223-015-0105-3","volume":"98","author":"I Piec","year":"2016","unstructured":"Piec I, Washbourne C, Tang J, Fisher E, Greeves J, Jackson S, Fraser WD (2016) How accurate is your sclerostin measurement? Comparison between three commercially available sclerostin ELISA kits. Calcif Tissue Int 98:546\u2013555","journal-title":"Calcif Tissue Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-019-02290-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-019-02290-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T19:13:03Z","timestamp":1602529983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-019-02290-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2290"],"URL":"https:\/\/doi.org\/10.1007\/s11255-019-02290-3","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}